Weekly administration of 40,000 units of recombinant human erythropoietin (rHuEPO) reduces allogeneic red blood cell (RBC) transfusion and increases haemoglobin in critically ill patients.
Researchers in the United States say further research is needed to determine, however, whether the reduction in RBC transfusion results in improved clinical outcomes in the critically ill. “Despite receiving fewer RBC transfusions, patients treated with rHuEPO achieve a higher haemoglobin level, consistent with the hypothesis that the anaemia of critical illness is an underproduction anaemia characterized in part by a relative erythropoietin deficiency,” say investigators led by Dr. Howard Corwin of the Dartmouth-Hitchcock Medical Centre in Lebanon, New Hampshire.
“No differences in clinical outcomes were demonstrated between rHuEPO and placebo groups. Therefore, while it is clear that rHuEPO treatment reduces RBC transfusions in critically ill patients, further study is necessary to establish whether this reduction will also result in improved clinical outcomes for some critically ill patients.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!